Researchers develop a new class of covalent inhibitor for a protein involved in brain diseases Blog Post

An article published in Cell Chemical Biology by scientists at the Institute for Research in Biomedicine (IRB Barcelona) in Barcelona Science Park (PCB) describes a new class of prolyl oligopeptidase (POP) inhibitors. Found mostly in the brain, POP protein has emerged as an “attractive·” therapeutic target for the treatment of several cognitive and neurodegenerative disorders, such as Parkinson’s disease and schizophrenia.The work was done in collaboration with the biotech Iproteos, based in PCB and scientists at the University of Glasgow (Scotland, UK) and the Utrecht Institute for Pharmaceutical Sciences (the Netherlands). The study has also involved the Nuclear Magnetic Resonance Laboratory (LRB) –wich is part of CCiTUB and it’s located in the Cluster building of the Park– and the Barcelona Supercomputing Center (BSC).

 

Scientific and Technological Centers UB: 30 years of technology serving research and innovation Blog Post

The Scientific and Technological Centers of the University of Barcelona (CCiTUB) reached their first thirty years of activity over which they have become widely known in both the national and international fields of research, innovation, and transfer. At the moment, the team in CCiTUB is formed by a hundred and sixty experts and administration staff, and eighty of tem are doctors, distributed in thirty-eight units, six of which are located in the Barcelona Science Park (PCB), among which there is the Nuclear Magnetic Resonance Laboratory (LRB), listed in the Map of Unique Scientific and Technical Infraestructures (ICTS). 

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

Cebiotex launches a €650,000 crowdfunding campaign to ensure that its oncological treatment reaches paediatrics Blog Post

Cebiotex—with headquarters in the Barcelona Science Park (PCB)—has launched an equity crowdfunding campaign of €650,000 through Capital Cell to ensure that its first drug, CEB-01, used in the local post-surgical treatment of soft tissue sarcomas, also reaches paediatric oncology. CEB-01 is the first therapeutic application of its innovative technology, which are based on nanofibres, for local drug delivery. In the future, however, the company aims to develop new applications for pancreatic and liver cancer, as well as glioblastoma.Since it was formed in 2012, Cebiotex has raised over €2 million from public and private funds. The success of the previous equity crowdfunding campaigns and the participation of impactful social investors has allowed Cebiotex to maintain a paediatric focus as one of the company’s strategic objectives.

 

The PCB receives the secondary award for best practice in science and technology parks of APTE Blog Post

Ignasi Belda, CEO of the Barcelona Science Park (PCB), has received this morning the secondary prize of the ‘Award for best practice in science and technology parks of Apte’ in the category of parks with an age of more than 10 years. The award ceremony has been delivered within the framework of the XV International Conference of the Association of Science and Technology Parks of Spain (APTE), which is being held today at the Gipuzkoa Science and Technology Park under the name “Beyond 2020: disruptive technologies“.

 

Catalan biomedical companies attracted €153.1 million in investment in 2016 Blog Post

Catalan biomedical companies were able to attract €153.1 million in investment in 2016, a record figure for the sector. This is the main takeaway from the first Study on investment in the Biomedical industry in Catalonia 2017: Achievements and future challenges presented by CataloniaBio, based at the Barcelona Science Park, and EY at the Cercle d’Economia before some seventy members of the association, entrepreneurs, investors and other professionals. 

 

A team of UB and PCB takes part in the licence of a new technology of fluorescent dyes of biomedical interest Blog Post

A new article published in the journal Nature Protocols describes the new technology to develop a series of activable fluorophores that enable the peptide molecular labelling and improve cell-live imaging. The new study has the participation of the teams led by Rodolfo Lavilla, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Barcelona Science Park (PCB), and Marc Vendrell, from the Edinburgh Medical School (Scotland).    

 

The Institute of Cosmos Sciences sets up a technology unit at the Barcelona Science Park Blog Post

The Institute of Cosmos Sciences of the UB (ICCUB) has set up a Technology Unit (ICCUB-Tech) at the Barcelona Science Park to develop highly specialized instrumentation and massive data analysis for scientific and technology projects, as well as for companies. With this initiative, the center – one of the four units that make up the Institute of Space Studies of Catalonia (IEEC)– wants to apply the expertise acquired in space science and particle physics projects to other fields, such as medicine, genomics and marine geociences.

 

Esteve y Farmamundi renew their collaboration agreement to provide humanitarian aid Blog Post

Esteve and Farmamundi have renewed their collaboration agreement once again, under which the laboratory participates as a member of the organization’s emergency fund and, at the same time, as a provider of medicines. The medical and pharmaceutical material donated by esteve in 2016 were distributed to hospitals, clinics, health centers, welcome centers for sick people, refugee camps, orphanages and nursing homes in 23 countries.